Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells

J Biophotonics. 2021 Apr;14(4):e202000496. doi: 10.1002/jbio.202000496. Epub 2021 Mar 1.

Abstract

The study of any intervention able to counteract SARS-CoV-2 pandemic is considerably envisaged. It was previously shown, in in vitro models of infections, that the LED blue light is able to decrease the viral load of HSV-1 and ZIKV. In our study, LED photobiomodulation therapy (PBMT) at blue wavelengths (450, 454 and 470 nm) was tested in an in vitro model of SARS-CoV-2 infection, employing three experimental settings: SARS-CoV-2 was irradiated and then transferred to cells; already infected cells were irradiated; cells were irradiated prior to infection. A decrement of the viral load was observed when previously infected cells were irradiated with all three tested wavelengths and relevant effects were registered especially at 48 hours post-infection, possibly suggesting that the blue light could interfere with the intracellular viral replication machinery. Our in vitro findings could represent the starting point for translational applications of PBMT as a supportive approach to fight SARS-CoV-2.

Keywords: SARS-CoV-2; Vero E6 cell line; blue LED; photobiomodulation therapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • COVID-19
  • Chlorocebus aethiops
  • Low-Level Light Therapy*
  • SARS-CoV-2 / radiation effects*
  • Vero Cells
  • Viral Load*